钙/钙调蛋白依赖性蛋白激酶II与真核延伸因子2激酶通路介导氯胺酮的抗抑郁作用
该研究在野生型C57BL/6小鼠中使用CaMKII特异性抑制剂tatCN21肽,并利用eEF2K敲除小鼠,通过强迫游泳、悬尾和新型抑制进食测试进行生化与行为分析。结果显示eEF2K敲除消除了eEF2在苏氨酸56位点的磷酸化,增加蛋白质合成,并使小鼠在生化和行为上对氯胺酮的抗抑郁效应产生抵抗;氯胺酮给药导致海马和皮层中CaMKIIα的差异性调控,表现为自抑制(pT305磷酸化)后自激活(pT286)。结论提示靶向CaMKs和调节蛋白质合成的药物为重度抑郁症治疗提供新策略。
要点
- eEF2K敲除小鼠对氯胺酮的抗抑郁效应产生生化与行为抵抗。
- 氯胺酮诱导海马和皮层CaMKIIα先自抑制后自激活。
- 全身给予CaMKII抑制剂tatCN21增加整体蛋白合成并诱导行为性氯胺酮抵抗。
核心结论
- 靶向CaMKs和调节蛋白质合成的药物可能为重度抑郁症治疗提供新策略。
研究设计与样本
- 研究使用野生型C57BL/6小鼠给予CaMKII特异性抑制剂tatCN21肽,并使用eEF2K敲除小鼠,进行生化与行为分析。
- 行为学测试包括强迫游泳、悬尾和新型抑制进食测试。
主要发现
- eEF2K敲除消除了eEF2在苏氨酸56位点的磷酸化,导致蛋白质合成增加。
- eEF2K敲除小鼠在生化和行为上对氯胺酮的抗抑郁效应产生抵抗。
- 氯胺酮给药导致海马和皮层中CaMKIIα自抑制(pT305磷酸化)后自激活(pT286)。
- CaMKII抑制阶段在氯胺酮给药后持续10至20分钟,与eEF2K依赖的蛋白质合成增加同时发生。
- 氯胺酮给药依赖的GluA1延迟诱导(24小时)受CaMKII激活调控;全身给予tatCN21增加整体蛋白质合成并诱导行为性氯胺酮抵抗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ketamine is an N-methyl-D-aspartate receptor antagonist, which on administration produces fast-acting antidepressant responses in patients with major depressive disorder. Yet, the mechanism underlying the antidepressant action of ketamine remains unclear. METHODS: To unravel the mechanism of action of ketamine, we treated wild-type C57BL/6 mice with calcium/calmodulin-dependent protein kinase II (CaMKII) specific inhibitor tatCN21 peptide. We also used eukaryotic elongation factor 2 kinase (eEF2K) (also known as CaMKIII) knockout mice. We analyzed the effects biochemically and behaviorally, using the forced swim, tail suspension, and novelty suppressed feeding tests. RESULTS: Consistent with the literature, one of the major pathways mediating the antidepressant action of ketamine was reduction of phosphorylation of eEF2 via eEF2K. Specifically, knocking out eEF2K in mice eliminated phosphorylation of eEF2 at threonine at position 56, resulting in increased protein synthesis, and made mice resistant both biochemically and behaviorally to the antidepressant effects of ketamine. In addition, administration of ketamine led to differential regulation of CaMKII function, manifested as autoinhibition (pT305 phosphorylation) followed by autoactivation (pT286) of CaMKIIα in the hippocampus and cortex. The inhibition phase of CaMKII, which lasted 10 to 20 minutes after administration of ketamine, occurred concurrently with eEF2K-dependent increased protein synthesis. Moreover, ketamine administration-dependent delayed induction of GluA1 (24 hours) was regulated by the activation of CaMKII. Importantly, systemic administration of the CaMKII inhibitor tatCN21 increased global protein synthesis and induced behavioral resistance to ketamine. CONCLUSIONS: Our data suggest that drugs that selectively target CaMKs and regulate protein synthesis offer novel strategies for treatment of major depressive disorder.
引用
- Adaikkan C, Taha E, Barrera I, et al. Calcium/Calmodulin-Dependent Protein Kinase II and Eukaryotic Elongation Factor 2 Kinase Pathways Mediate the Antidepressant Action of Ketamine. Biol Psychiatry. 2017. PMID: 29395043. doi:10.1016/j.biopsych.2017.11.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。